Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Teva Pharmaceutical (TEVA.TA) and Viatris (VTRS.O) convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson (JNJ.N) schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.